

Florian Gebauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/149423/publications.pdf>

Version: 2024-02-01

47
papers

1,123
citations

516710

16
h-index

434195

31
g-index

49
all docs

49
docs citations

49
times ranked

1879
citing authors

#	ARTICLE	IF	CITATIONS
1	A new hybrid stent using endoscopic vacuum therapy in treating esophageal leaks: a prospective single-center experience of its safety and feasibility with mid-term follow-up. <i>Ecological Management and Restoration</i> , 2022, 35, .	0.4	17
2	Expression of Neighbor of Punc E11 (NOPE) in early stage esophageal adenocarcinoma is associated with reduced survival. <i>Scientific Reports</i> , 2022, 12, 3584.	3.3	0
3	International Tumor Budding Consensus Conference criteria determine the prognosis of oesophageal adenocarcinoma with poor response to neoadjuvant treatment. <i>Pathology Research and Practice</i> , 2022, 232, 153844.	2.3	2
4	Influence of patient sex on outcomes after pancreatic surgery: multicentre study. <i>British Journal of Surgery</i> , 2022, 109, 746-753.	0.3	4
5	Long-Term Outcome After Histopathological Complete Response with and Without Nodal Metastases Following Multimodal Treatment of Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4419-4428.	1.5	10
6	Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , .	2.5	3
7	Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 393-400.	2.8	13
8	GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1031-1040.	2.5	5
9	Aldo-Keto Reductase 1C3 Mediates Chemotherapy Resistance in Esophageal Adenocarcinoma via ROS Detoxification. <i>Cancers</i> , 2021, 13, 2403.	3.7	14
10	Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma. <i>Gastric Cancer</i> , 2021, 24, 1213-1226.	5.3	16
11	Endoscopic vacuum therapy versus stent treatment of esophageal anastomotic leaks (ESOLEAK): study protocol for a prospective randomized phase 2 trial. <i>Trials</i> , 2021, 22, 377.	1.6	14
12	Gastrointestinal function testing model using a new laryngopharyngeal pH probe (Restech) in patients after Ivor-Lewis esophagectomy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 612-624.	2.0	2
13	Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOI.PANC). <i>BMC Cancer</i> , 2021, 21, 1239.	2.6	16
14	Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers. <i>Seminars in Cancer Biology</i> , 2020, 60, 334-343.	9.6	32
15	True single-port cholecystectomy with ICG cholangiography through a single 15-mm trocar using the new surgical platform "œsymphonX" first human case study with a commercially available device. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 2722-2729.	2.4	10
16	Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 12.	2.6	35
17	PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. <i>Translational Oncology</i> , 2020, 13, 157-164.	3.7	29
18	Does Circular Stapler Size in Surgical Management of Esophageal Cancer Affect Anastomotic Leak Rate? 4-Year Experience of a European High-Volume Center. <i>Cancers</i> , 2020, 12, 3474.	3.7	20

#	ARTICLE	IF	CITATIONS
19	New insights into benefits of combination treatment with yttrium-90 and gemcitabine in patients with intrahepatic cholangiocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 833-835.	1.4	0
20	Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival. <i>Pancreas</i> , 2020, 49, 1307-1314.	1.1	1
21	Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. <i>Scientific Reports</i> , 2020, 10, 18411.	3.3	22
22	Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091757.	3.2	10
23	Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2319-2327.	2.5	25
24	Y Chromosome Loss Is a Frequent Event in Barrett's Adenocarcinoma and Associated with Poor Outcome. <i>Cancers</i> , 2020, 12, 1743.	3.7	8
25	Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma. <i>Cancers</i> , 2020, 12, 451.	3.7	7
26	Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 523-533.	4.2	19
27	Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. <i>Oncology Letters</i> , 2020, 19, 3665-3670.	1.8	13
28	High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients. <i>Experimental and Molecular Pathology</i> , 2019, 107, 51-56.	2.1	1
29	Aberrant expression of Sec61 in esophageal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2039-2044.	2.5	0
30	Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 531.	2.6	12
31	The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. <i>OncImmunology</i> , 2019, 8, e1581546.	4.6	59
32	Proposal for a definition of "Oligometastatic disease in pancreatic cancer". <i>BMC Cancer</i> , 2019, 19, 1261.	2.6	34
33	HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 38.	2.6	59
34	Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 69-78.	6.4	55
35	Genomic Characterization of TP53 in Wild-Type Esophageal Carcinoma. <i>Translational Oncology</i> , 2019, 12, 154-161.	3.7	8
36	Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2844-2850.	7.0	78

#	ARTICLE	IF	CITATIONS
37	Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. <i>Surgery</i> , 2016, 160, 136-144.	1.9	121
38	Tenascin-C serum levels and its prognostic power in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20945-20952.	1.8	12
39	Establishment and Characterization of a Pair of Patient-derived Human Non-small Cell Lung Cancer Cell Lines from a Primary Tumor and Corresponding Lymph Node Metastasis. <i>Anticancer Research</i> , 2016, 36, 1507-18.	1.1	1
40	Resection Margin Clearance in Pancreatic Cancer After Implementation of the Leeds Pathology Protocol (LEPP): Clinically Relevant or Just Academic?. <i>World Journal of Surgery</i> , 2015, 39, 493-499.	1.6	69
41	Glomangioma of the lung: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2014, 8, 5.	0.8	5
42	ABO Blood Group IgM Isoagglutinins Interact with Tumor-Associated O-Glycan Structures in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6117-6126.	7.0	28
43	Carcinoembryonic Antigen-Related Cell Adhesion Molecules (CEACAM) 1, 5 and 6 as Biomarkers in Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e113023.	2.5	76
44	Serum EpCAM expression in pancreatic cancer. <i>Anticancer Research</i> , 2014, 34, 4741-6.	1.1	9
45	Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in <i>pfp</i> ^{+/+} / <i>rag2</i> ^{+/+} mice. <i>Gut</i> , 2013, 62, 741-750.	12.1	48
46	Options and Limitations in Applying the Fistula Classification by the International Study Group for Pancreatic Fistula. <i>Annals of Surgery</i> , 2012, 256, 130-138.	4.2	51
47	Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 140-145.	1.7	49